New
Trackinsight is part of ETF One, the fully integrated ETF platform of Kepler Cheuvreux. Learn more →
Help us improve your experience. Please confirm your investor type:
Compare ETFs Easily
The Ultimate ETF Comparison Tool - Try Now!
Analyze up to 5 ETFs side-by-side and gain instant insights on performance, fees, holdings, and more to make data-driven investment decisions.
185680 ETF · Samsung KODEX SYNTH-US Biotech ETF
The 185680 Exchange Traded Fund (ETF) is provided by Samsung Asset Management. It is built to track an index: S&P Biotechnology Select Industry Index. This ETF provides synthetic exposure, by owning its shares you earn the return of the index indirectly through the use of derivatives or a swap (i.e. a contract with a financial institution which delivers the return of the index). This share class generates a stream of income by distributing dividends.
Last update Today at 12:00 AM UTC
LIVE
CLOSED
This fund is part ofUS Health Care1M perf.+2.20%
Last price
â‚©42,845
1M perf.
+10.15%
1M flows
+€447K
AuM
€13M
E/R
0.25%
Rating
Not rated
ESG Consensus®
185680
â‚©42,845
Performance & flows
Segment for quartile rank
January 22, 2026 → April 22, 2026
Create a free account to view the flows graph
185680
â‚©43,129.12
+6.57%
US Health Care
-5.66%
Historic performance and flows
| 1M | 3M | 1Y | 3Y | 5Y | MTD | QTD | YTD | ||
|---|---|---|---|---|---|---|---|---|---|
| Perf. | +10.15%  | +6.57% | +85.95% | +81.38% | +33.26% | +10.62% | +10.62% | +12.48% | |
| Flows |
Key fund info
Segment for quartile rank
This ETF's jurisdiction country is not in your region (Europe and Middle East) ·
Main characteristics
Issuer
ISIN
KR7185680006
AuM
€13M
E/R
0.25%
Replication rating
Not rated
ESG Consensus®
More details
NAV
4/22/2026
â‚©43,129.12
1D NAV change
-0.46%
Dividend policy
Replication method
Indirect
Replication model
No. of holdings
151
Inception date
10/30/2013
Jurisdiction
South Korea
Distribution
South Korea
Legal structure
Open-end Investment Trust
Base currency
KRW
Dividend distribution
Trailing 12-month distr. yield
Distribution frequency
Last distribution
Create a free account to view dividend distribution
Classification
Investment strategy
Samsung KODEX SYNTH-US Biotech ETF tracks the performance of the S&P Biotechnology Select Industry Index.
Tax optimisation
PEA
France
UK Reporting Status
United Kingdom
Create a free Trackinsight Essentials account to unlock insights
Access exclusive metrics and features to support your investment decisions.
New to Trackinsight?
For individual investors
Essentials
A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.
More fund data
Compare up to 3 funds
More screener filters
Choose your own screener columns from 100+ metrics
Lists for saving your research
Portfolio construction and analysis
Personal dashboard for live monitoring
For professional investors
Enterprise
Trackinsight Enterprise addresses the everyday operational, regulatory, and analytical pain points faced by professional and institutional ETF investors, from selection to execution.
Request a free trialAdvertisement
Risk profile
Segment for quartile rank
Historical risk/return profile
| 3M | 1Y | 3Y | 5Y | |
|---|---|---|---|---|
| Returns | +6.57% | +85.95% | +81.38% | +33.26% |
| Volatility | ||||
| Perf./Volatility | ||||
| Max drawdown |
Create a free account to view risk/return table
Synthetic Risk and Reward Indicator (SRRI)
UCITS
N/A
PRIIPS
N/A
More exposure metrics are available, exclusively in Trackinsight Enterprise
Exposure
Exposure based on a proxy
More info
Countries
USA
95.16%
Ireland
1.58%
Switzerland
1.09%
Bermuda
1.07%
Other
1.02%
Sectors
Health Care
86.79%
Unavailable
13.14%
Diversification
Exposure based on a proxy
More info
Total weight of top 15 holdings out of 151
Top 15 holdings
Data as of March 31, 2026
Exposure based on a proxy
More info
APELLIS PHARMACEUTICALS
ALKERMES
MADRIGAL PHARMACEUTICALS INC
TG THERAPEUTICS
INSMED
SCHOLAR ROCK HOLDING CORP
US03770N1019
PROTAGONIST THERAPEUTICS INC
Create a free account to view top holdings
US86627T1088
UTD THERAPEUT
US74006W2070
ARROWHEAD PHARMACEUTICALS INC
COGENT BIOSCIENCES
BRIDGEBIO PHARMA
PTC THERAPEUTI/D
Create a free account to view top holdings
More risk metrics are available, exclusively in Trackinsight Enterprise
Sustainability
Integrates ESG criteria
No
SDG
More sustainability metrics are available, exclusively in Trackinsight Enterprise
Issuer
Samsung Asset Management
Samsung Asset Management ID Card
Number of funds
145
Total AuM
€64.31B
Expense ratio range
0.015% - 2.28%
Average expense ratio
0.3679%
Top 5 funds by Samsung Asset Management
| AuM | ||
|---|---|---|
069500 | Samsung KODEX 200 ETF | €12.72B |
379800 | KODEX S&P500 TR | €4.92B |
459580 | Samsung Kodex CD Rate Active(SYNTH) ETF | €4.68B |
278530 | Samsung KODEX 200 Total Return ETF | €3.89B |
229200 | Samsung KODEX KOSDAQ 150 ETF | €3.82B |
Frequently asked questions about 185680
What does Samsung KODEX SYNTH-US Biotech ETF, 185680, invest in?
185680 is a Passive ETF. This ETF provides exposure to Equally Weighted US Biotechnology Equities.
Which benchmark or index does 185680 replicate?
185680 tracks the S&P Biotechnology Select Industry Index - USD, through a replication method.
What is the Total Expense ratio (TER) of 185680?
185680 carries a total expense ratio (TER) of 0.25%, indicating the annual cost for holding the fund.
When was 185680 launched?
185680 was introduced to the market on October 30, 2013. It trades on South Korea
Who is the ETF issuer of 185680?
Samsung KODEX SYNTH-US Biotech ETF, 185680, is provided by Samsung Asset Management. Learn more about Samsung Asset Management here.
What is the current assets under management (AUM) of 185680?
185680 oversees €13M in assets as of April 22, 2026.
How has 185680 performed lately?
Based on data from April 22, 2026, 185680 returned 10.15% over the past month, 6.57% over the last three months and 12.48% year-to-date.
What are the latest inflows or outflows for 185680?
As of April 22, 2026, 185680 recorded net flows of +€449K over the last month and -€69K year-to-date.
Does 185680 distribute dividends?
185680 follows a distributing dividend policy, meaning it pays out income to investors.
What are the main country or region exposures of 185680?
As of March 31, 2026, 185680 has significant geographic allocations in USA, Ireland and Switzerland.
In which sector or theme does 185680 invest in?
As of March 31, 2026, 185680 focuses largely on Health Care.
How many securities does 185680 hold and how diversified is it?
As of March 31, 2026, 185680 holds 151 positions in its portfolio, with 19.71% of assets concentrated in its top 15 holdings.
What are the main positions in 185680?
As of March 31, 2026, 185680 top three holdings include APELLIS PHARMACEUTICALS, ALKERMES and MADRIGAL PHARMACEUTICALS INC.
What is the base currency of 185680?
The base currency of 185680 is KRW.
Advertisement
About Trackinsight
Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.
Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.
In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.
This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.
Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.
More about TrackinsightETF TOOLS
PLATFORM
ETF NEWS & RESEARCH
© 2014-2026 Trackinsight SA. All rights reserved.
Privacy policy | Cookie policy | | Terms of use | Imprint
Privacy policy | Cookie policy | | Terms of use | Imprint
